莫沙必利联合雷贝拉唑治疗老年人反流性食管炎的临床疗效分析
|
摘要
目的探讨莫沙必利联合雷贝拉唑治疗老年人反流性食管炎的临床疗效。方法选取本院2016年1月至2018年6月接收的150例老年人反流性食管炎患者,随机分为观察组与对照组,每组75例,分别接受莫沙必利联合雷贝拉唑治疗、莫沙必利联合奥美拉唑治疗。对比治疗效果,并观察治疗后患者症状积分、CRP水平、降钙素原水平、不良反应发生情况。结果观察组治疗总有效率较对照组更高(P<0.05);观察组治疗后反酸、烧灼感、剑突下疼痛症状积分较对照组均更低(P<0.05);观察组治疗后CRP水平、降钙素原水平较对照组均更低(P<0.05);观察组总不良反应发生率较对照组更低(P<0.05),差异均有统计学意义。结论莫沙必利联合雷贝拉唑用药可有效改善老年人反流性食管炎患者的临床症状,缓解炎症,促进快速康复,且临床治疗安全性较高,可推广使用。
Objective To investigate the clinical efficacy of Mosapride combined with Rabeprazole in the treatment of reflux esophagitis in the elderly. Methods 150 elderly patients with reflux esophagitis received from January 2016 to June 2018 were randomly divided into observation group and control group, with 75 cases in each group. They were treated with Mosapride combined with Rabeprazole and Mosapride combined with Omeprazole. The therapeutic effects were compared, and the symptom scores, CRP levels, procalcitonin levels, and adverse reactions were observed after treatment. Results The total effective rate of the observation group was higher than that of the control group(P<0.05). The scores of acid reflux, burning sensation and subxiphoid pain in the observation group were lower than those in the control group(P<0.05). The levels of CRP and procalcitonin in the observation group were lower than those in the control group(P<0.05). The incidence of total adverse reactions in the observation group was lower than that in the control group(P<0.05). The differences were statistically significant. Conclusion Mosapride combined with rabeprazole can effectively improve the clinical symptoms of elderly patients with reflux esophagitis, alleviate inflammation, promote rapid recovery, and the clinical treatment is safe and can be widely used.
Objective To investigate the clinical efficacy of Mosapride combined with Rabeprazole in the treatment of reflux esophagitis in the elderly. Methods 150 elderly patients with reflux esophagitis received from January 2016 to June 2018 were randomly divided into observation group and control group, with 75 cases in each group. They were treated with Mosapride combined with Rabeprazole and Mosapride combined with Omeprazole. The therapeutic effects were compared, and the symptom scores, CRP levels, procalcitonin levels, and adverse reactions were observed after treatment. Results The total effective rate of the observation group was higher than that of the control group(P<0.05). The scores of acid reflux, burning sensation and subxiphoid pain in the observation group were lower than those in the control group(P<0.05). The levels of CRP and procalcitonin in the observation group were lower than those in the control group(P<0.05). The incidence of total adverse reactions in the observation group was lower than that in the control group(P<0.05). The differences were statistically significant. Conclusion Mosapride combined with rabeprazole can effectively improve the clinical symptoms of elderly patients with reflux esophagitis, alleviate inflammation, promote rapid recovery, and the clinical treatment is safe and can be widely used.
引文
[1]赵兴彬,黑晓东.雷贝拉唑、莫沙必利和铝镁加联合治疗反流性食管炎的临床疗效[J].中国实用医药,2016,11(18):193-194.
[2]赵玲玲.莫沙必利联合雷贝拉唑治疗老年反流性食管炎的临床疗效与安全性评价[J].北方药学,2016,13(10):144-145.
[3]徐文俊,许建国,朱华,等.雷贝拉唑或奥美拉唑联合莫沙必利治疗反流性食管炎有效性和安全性的meta分析[J].药学与临床研究,2017,25(2):145-148.
[4]朱方丽.雷贝拉唑联合莫沙必利治疗反流性食管炎的临床效果[J].中医临床研究,2017,9(22):118-119.
[5]崔涛,周娜,李建坤.莫沙必利+雷贝拉唑治疗反流性食管炎临床疗效及内镜下征象改善效果评价[J].饮食保健,2016,3(20):50-51.
[6]王莉娟,宋琪.氟哌噻吨美利曲辛与莫沙必利、雷贝拉唑联合治疗反流性食管炎的疗效观察[J].中国医药指南,2017,15(15):142.
[7]卢晨霞,施正君,王雪明.氟哌噻吨美利曲辛联合雷贝拉唑、莫沙必利治疗非糜烂性反流性食管炎疗效观察[J].青岛医药卫生,2017,49(4):256-259.
[8]赵雅琴.莫沙必利联合雷贝拉唑不同疗程缓解反流性食管炎症状的对比研究[J].现代医药卫生,2016,32(6):921-922.
[9]司丽.莫沙必利联合奥美拉唑治疗胃癌术后反流性食管炎的疗效分析[J].中国现代药物应用,2016,10(11):120-121.
[10]黎可京,邱小蕾.莫沙必利联合奥美拉唑治疗反流性食管炎的临床疗效及安全性分析[J].医学理论与实践,2017,30(5):683-684.
[11]杭海.联用黛力新、莫沙必利和雷贝拉唑治疗慢性胃炎合并反流性食管炎的效果评价[J].当代医药论丛,2017,15(22):82-83.
[12]张静.莫沙必利与埃索美拉唑联合治疗88例老年反流性食管炎效果观察[J].临床合理用药杂志,2016,9(32):56-57.
[13]金文成,孙禹威.雷贝拉唑联合莫沙必利治疗反流性食管炎临床疗效和安全性的Meta分析[J].中国医药指南,2016,14(20):41-43.
[14]陈乔,杨聪玲.雷贝拉唑联合莫沙必利治疗反流性食管炎的疗效观察[J].中国生化药物杂志,2017,37(6):304-306.
[15]赖新兰,杨新魁,刘水清,等.莫沙必利联合雷贝拉唑钠治疗反流性食管炎的临床研究[J].现代药物与临床,2016,31(10):1538-1541.
[2]赵玲玲.莫沙必利联合雷贝拉唑治疗老年反流性食管炎的临床疗效与安全性评价[J].北方药学,2016,13(10):144-145.
[3]徐文俊,许建国,朱华,等.雷贝拉唑或奥美拉唑联合莫沙必利治疗反流性食管炎有效性和安全性的meta分析[J].药学与临床研究,2017,25(2):145-148.
[4]朱方丽.雷贝拉唑联合莫沙必利治疗反流性食管炎的临床效果[J].中医临床研究,2017,9(22):118-119.
[5]崔涛,周娜,李建坤.莫沙必利+雷贝拉唑治疗反流性食管炎临床疗效及内镜下征象改善效果评价[J].饮食保健,2016,3(20):50-51.
[6]王莉娟,宋琪.氟哌噻吨美利曲辛与莫沙必利、雷贝拉唑联合治疗反流性食管炎的疗效观察[J].中国医药指南,2017,15(15):142.
[7]卢晨霞,施正君,王雪明.氟哌噻吨美利曲辛联合雷贝拉唑、莫沙必利治疗非糜烂性反流性食管炎疗效观察[J].青岛医药卫生,2017,49(4):256-259.
[8]赵雅琴.莫沙必利联合雷贝拉唑不同疗程缓解反流性食管炎症状的对比研究[J].现代医药卫生,2016,32(6):921-922.
[9]司丽.莫沙必利联合奥美拉唑治疗胃癌术后反流性食管炎的疗效分析[J].中国现代药物应用,2016,10(11):120-121.
[10]黎可京,邱小蕾.莫沙必利联合奥美拉唑治疗反流性食管炎的临床疗效及安全性分析[J].医学理论与实践,2017,30(5):683-684.
[11]杭海.联用黛力新、莫沙必利和雷贝拉唑治疗慢性胃炎合并反流性食管炎的效果评价[J].当代医药论丛,2017,15(22):82-83.
[12]张静.莫沙必利与埃索美拉唑联合治疗88例老年反流性食管炎效果观察[J].临床合理用药杂志,2016,9(32):56-57.
[13]金文成,孙禹威.雷贝拉唑联合莫沙必利治疗反流性食管炎临床疗效和安全性的Meta分析[J].中国医药指南,2016,14(20):41-43.
[14]陈乔,杨聪玲.雷贝拉唑联合莫沙必利治疗反流性食管炎的疗效观察[J].中国生化药物杂志,2017,37(6):304-306.
[15]赖新兰,杨新魁,刘水清,等.莫沙必利联合雷贝拉唑钠治疗反流性食管炎的临床研究[J].现代药物与临床,2016,31(10):1538-1541.